NCT03292302 is a Phase 1 clinical trial of ELX-02 in Genetic Disease, sponsored by Eloxx Pharmaceuticals, Inc..

Who is sponsoring NCT03292302?

NCT03292302 is sponsored by Eloxx Pharmaceuticals, Inc..

What drugs are being tested in NCT03292302?

Interventions in NCT03292302: Placebo, ELX-02.

What condition does NCT03292302 study?

NCT03292302 studies Genetic Disease, Nonsense Mutation.

Is NCT03292302 still recruiting?

NCT03292302 is currently completed. Last updated 22 August 2023.

Last reviewed 2023-08-22 · How we verify

NCT03292302

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study of ELX-02 in Healthy Adults

Completed Phase 1 Last updated 22 August 2023

What this trial tests

Phase 1 trial testing Placebo in Genetic Disease in 18 participants. Completed in 15 December 2017.

Timeline

26 September 2017

Primary endpoint
15 December 2017

15 December 2017

Quick facts

Lead sponsor	Eloxx Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	18
Start date	26 September 2017
Primary completion	15 December 2017
Estimated completion	15 December 2017
Sites	1 location across Belgium

Drugs / interventions tested

Placebo
ELX-02 — full drug profile →

Conditions studied

Genetic Disease — all drugs for Genetic Disease →
Nonsense Mutation — all drugs for Nonsense Mutation →

Sponsor

Eloxx Pharmaceuticals, Inc.

Who can join

Adults 18 to 45, any sex, with Genetic Disease or Nonsense Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1 Single Ascending Dose Study in Normal Healthy Volunteers

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis.
Pinto MC, Silva IAL, Figueira MF, Amaral MD, et al · · 2021 · cited 37× · PMID 34326672 · DOI 10.2147/jep.s255377
One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
Ensinck MM, Carlon MS. · · 2022 · cited 24× · PMID 35740997 · DOI 10.3390/cells11121868
Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
Li S, Li J, Shi W, Nie Z, et al · · 2023 · cited 21× · PMID 37371567 · DOI 10.3390/biom13060988

Verify or expand the search:

Other trials of ELX-02

Trials testing the same drug.

NCT05448755 — A Study of ELX-02 in Patients With Alport Syndrome · Phase 2 · completed
NCT04135495 — A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele · Phase 2 · completed
NCT04126473 — A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele · Phase 2 · completed
NCT04069260 — A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis · Phase 2 · terminated
NCT03776539 — A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02 · Phase 1 · completed

Other recruiting trials for Genetic Disease

Currently open trials in the same condition.

NCT06744543 — Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease · NA · active not recruiting
NCT06435468 — Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases · NA · recruiting
NCT06821386 — N-Care Project: Enhancing Asian-Pacific Collaboration · recruiting
NCT07365254 — Accurate Assessment and Intervention Research on Newborn Whole Genome Sequencing and Genetic Disease Risk · recruiting
NCT06725901 — Pediatric Neurogenetic Diagnosis Support Platform · NA · recruiting

Other Eloxx Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT07523581 — EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety · Phase 2 · not yet recruiting
NCT05448755 — A Study of ELX-02 in Patients With Alport Syndrome · Phase 2 · completed
NCT04135495 — A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele · Phase 2 · completed
NCT04126473 — A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele · Phase 2 · completed
NCT04069260 — A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03292302 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eloxx Pharmaceuticals, Inc.
Last refreshed: 22 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03292302.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing